This site requires Flash 8.

If you are seeing this message it indicates that Flash has not been properly installed.

You can install Flash by visiting the Adobe website or clicking here.

About Us

Your Dream is our Vision: Life-saving medicines for life-threatening diseases

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs.

We focus on providing products to physician specialists that support patients with serious diseases for which there is an unmet medical need, including disease caused by C1 esterase inhibitor deficiency, C. difficile, and cytomegalovirus (CMV).

In everything we do, throughout our organization, we are committed to patient and physician needs, as we work to bring new products to markets with few, if any, therapeutic options. We are dedicated to transforming the promise of biotechnology into therapies that have the power to restore health and save lives.

Products and Pipeline
ViroPharma’s core focus is on providing patients and physicians new therapeutic alternatives for today’s great unmet medical needs.

Our product Cinryze™ (C1 Esterase Inhibitor [Human]) is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE), a rare and potentially life threatening genetic inflammatory disorder. Our product Vancocin® is the only antibiotic approved to treat two significant bacterial infections of the lower digestive tract. The product is administered orally and is indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by Clostridium difficile

The company is also assessing non-toxigenic C. difficile (NTCD) with the goals of preventing the recurrence of disease following effective therapy for acute C. difficile infection (CDI) and preventing CDI in patients who are susceptible to colonization with toxigenic strains due to prior use of antibiotics.

Corporate Goals
ViroPharma’s current clinical product portfolio serves as our foundation for growth, supported by revenues from product sales; and we are expanding on our franchise areas, by capitalizing on business execution and prudent business development.

ViroPharma is built on core values:  : customer focus, quality, passion, continuous improvement, courage, teamwork and integrity. These values are evident throughout ViroPharma: the way we conduct our business, the way we communicate with our various stakeholders, and in the manner in which we relate to one another.

At ViroPharma, we strive to improve healthcare by bringing new and important medicines to market.